Cash runway anticipated to be extended from Q2 2025 to Q4 2025 Data from multiple Phase 1 and 2 clinical trials expected in 2024 OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial